Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
New medical and science journals pop up in our mailbox on a biweekly basis. Offers to join as Editor, solicitation for articles based on past publications, invitations for subject reviews come as unsolicited emails. Medical publication houses, old and new, are expanding, adding more and more subspecialties to their established Continue reading JOURNAL BUSINESS vs EDITORIAL OVERSIGHT
Today’s topic is about the lackluster recruitment of US centers in recent CABP trials. We noticed that Eastern European (EE) centers, specifically from Ukraine, Bulgaria, and Serbia, contribute patients in large numbers, actually making these trials feasible. When sponsors and CROs needed to enroll CABP patients, they could not rely Continue reading CABP TRIAL ENROLLMENT – BUT NOT IN THE USA
It started all so well with fanfare and great expectations. Fifteen years ago, the 10 x ’20 initiative got underway. Its goals were spelled out clearly: To ‘Pursue a Global Commitment to Develop 10 New Antibacterial Drugs by 2020 ’[3]. It was driven by ID clinicians and by antibiotic developers concerned Continue reading The 10 x ’20 Initiative – A Retrospective